Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prabotulinumtoxin A - Daewoong Pharmaceuticals

Drug Profile

Prabotulinumtoxin A - Daewoong Pharmaceuticals

Alternative Names: ABP 450; DWP-450; Evosyal; Jeuveau; Nabota; Nuceiva; Prabotulinumtoxin A; PrabotulinumtoxinA-xvfs

Latest Information Update: 26 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daewoong Pharmaceutical
  • Developer AEON Biopharma; Daewoong Pharmaceutical; Evolus; PPD
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Skin disorder therapies; Urologics
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glabellar lines
  • Phase III Muscle spasticity; Torticollis
  • Phase II/III Blepharospasm; Facial wrinkles
  • Phase II Migraine

Most Recent Events

  • 23 Aug 2021 AEON Biopharma plans a phase II extension trial for Migraine (Prevention) in USA (IM, Injection) in September 2021 (NCT05016661)
  • 07 May 2021 Daewoong Pharmaceutical announces intention to launch prabotulinumtoxin A in Turkey and Chile for Glabellar lines in Q3 2021
  • 06 May 2021 Registered for Glabellar lines in Chile, Turkey (IM) before May 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top